These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38034243)

  • 1. Effect of Intravitreal Brolucizumab in the Treatment of Polypoidal Choroidal Vasculopathy With Foveal Lipid Exudation.
    Carta V; Lixi F; Tatti F; Peiretti E
    Cureus; 2023 Oct; 15(10):e47942. PubMed ID: 38034243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kang KH; Yoon W; Lee J; Kim CG; Kim JW
    J Ocul Pharmacol Ther; 2023 Nov; 39(9):653-660. PubMed ID: 37504966
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and Effectiveness of Intravitreal Brolucizumab Injection in Combination With Sub-Tenon's Capsule Triamcinolone Acetonide Injection for Polypoidal Choroidal Vasculopathy During the Loading Phase.
    Yoshikawa Y; Sakaki Y; Shinoda K; Kataoka K
    Cureus; 2024 May; 16(5):e59481. PubMed ID: 38832144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy.
    Fukuda Y; Sakurada Y; Matsubara M; Kotoda Y; Kasai Y; Sugiyama A; Kashiwagi K
    Jpn J Ophthalmol; 2023 Jul; 67(4):402-409. PubMed ID: 37289296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy.
    Fukuda Y; Sakurada Y; Matsubara M; Hasebe Y; Sugiyama A; Kikushima W; Kashiwagi K
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy.
    Ito A; Maruyama-Inoue M; Kitajima Y; Ikeda S; Inoue T; Kadonosono K
    Sci Rep; 2022 May; 12(1):7987. PubMed ID: 35568780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of bilateral pachychoroid disease: polypoidal choroidal vasculopathy in one eye and peripheral exudative hemorrhagic chorioretinopathy in contralateral eye.
    Kitagawa Y; Shimada H; Kawamura A; Tanaka K; Mori R; Onoe H; Nakashizuka H
    BMC Ophthalmol; 2021 Sep; 21(1):320. PubMed ID: 34481477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy.
    Nam SW; Byun Z; Ham DI; Kong M
    BMC Ophthalmol; 2022 Dec; 22(1):485. PubMed ID: 36514022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
    Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study.
    Ueda-Consolvo T; Tanigichi A; Numata A; Oiwake T; Nakamura T; Ishida M; Yanagisawa S; Hayashi A
    Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):345-352. PubMed ID: 35947181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using optical coherence tomography angiography in assessment of the anti-vascular endothelial growth factor effect for pathological vascular tissue in age-related macular degeneration and polypoidal choroidal vasculopathy.
    Shen YS; Cheng CK
    Eur J Ophthalmol; 2021 May; 31(3):1267-1280. PubMed ID: 32228025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polypoidal choroidal vasculopathy].
    Yuzawa M
    Nippon Ganka Gakkai Zasshi; 2012 Mar; 116(3):200-31; discussion 232. PubMed ID: 22568102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
    Rouvas A; Gouliopoulos NS; Moschos MM; Theodossiadis P
    BMC Ophthalmol; 2018 Oct; 18(1):267. PubMed ID: 30309335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes - A multicenter retrospective study.
    Chakraborty D; Maiti A; Sengupta S; Mondal S; Nandi K; Chakraborty S
    Indian J Ophthalmol; 2022 Apr; 70(4):1295-1299. PubMed ID: 35326038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps.
    Lee SE; Jang JW; Kang SW; Park KH; Lee DW; Kim JH; Bae K
    Sci Rep; 2019 Feb; 9(1):1487. PubMed ID: 30728380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M; Matsumoto H; Mimura K; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
    Kim H; Lee SC; Kwon KY; Lee JH; Koh HJ; Byeon SH; Kim SS; Kim M; Lee CS
    Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1497-1503. PubMed ID: 26626772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.